• Silo Pharma posted a wider net loss of USD 1.65 million, versus a 59.7% increase from the year-ago quarter, as operating loss widened 45.7% to USD 1.59 million.
• Revenue was flat at USD 18,026, while cost of revenues more than doubled to USD 20,688, swinging gross profit to a loss of USD 2,662.
• Operating expenses climbed 43.33% to USD 1.59 million, led by research and development expense rising 70.6% to USD 1.01 million.
• Other expense turned to USD 52,457 from other income a year earlier, driven by unrealized loss on crypto assets of USD 53,348 and impairment loss of USD 29,911.
• Business updates included a USD 714,000 software asset acquisition tied to qwikagents.com, formation of wholly owned subsidiary Qwikagentsai, and a stock repurchase authorization of up to USD 1 million through Dec. 31, 2026 with no shares repurchased as of March 31.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-056079), on May 14, 2026, and is solely responsible for the information contained therein.